Recurrent absence status epilepticus (spike-and-wave stupor) associated with lamotrigine therapy

Journal of Child Neurology

Volumn 21, Issue 9, 2006, Pages 807-809

  Hasan, Mariana ^a   Lerman Sagie, Tally ^a   Lev, Dorit ^a   Watemberg, Nathan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DIAZEPAM; LAMOTRIGINE; METHYLPHENIDATE; MIDAZOLAM; PERIPHERAL MYELIN PROTEIN 22; RISPERIDONE; SULTIAME; VALPROIC ACID;

ABSENCE; ANAMNESIS; ARTICLE; BODY WEIGHT DISORDER; CASE REPORT; CHROMOSOME 17P; CLINICAL FEATURE; CONFUSION; CYANOSIS; DECREASED APPETITE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; FEMALE; GENE DELETION; HEREDITY; HUMAN; HYPERACTIVITY; NEUROLOGIC EXAMINATION; NEUROPATHY; OBSESSIVE COMPULSIVE DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENT DISEASE; RESTLESSNESS; SCHOOL CHILD; VOMITING; WEIGHT REDUCTION;

ANTICONVULSANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY, ABSENCE; FEMALE; HUMANS; STATUS EPILEPTICUS; STUPOR; TRIAZINES;

EID: 33750689183     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210090801     Document Type: Article

References (27)

1. Walker MC: Diagnosis and treatment of nonconvulsive status epilepticus. CNS Drugs 2001;15:931-939.
2. Cascino GD: Nonconvulsive status epilepticus in adults and children. Epilepsia 1993;34(Suppl 1):S21-828.
3. Kaplan PW: Nonconvulsive status epilepticus. Semin Neurol 1996;16: 33-40.
4. Perucca E, Gram L, Avanzini G, Dulac O: Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
5. Ettinger AB, Bernal OG, Andriola MR, et al: Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:1159-1162.
6. Coppola G, Auricchio G, Federico R, et al: Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: An open-label, randomized, parallel-group study. Epilepsia 2004;45:1049-1053.
7. Trinka E, Dilitz E, Unterberger I, et al: Nonconvulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002;249:1417-1422.
8. Tomson T, Lindbom U, Nilsson BY: Nonconvulsive status epilepticus in adults: Thirty-two consecutive patients from a general hospital population. Epilepsia 1992;33:829-835.
9. Primavera A, Cocito L, Audenino D: Nonconvulsive status epilepticus during cephalosporin therapy. Neuropsychobiology 2004;49:218-222.
10. Baykan B, Gökyǧit A, Gürses C, Eraksoy M: Recurrent absence status epilepticus: Clinical and EEG characteristics. Seizure 2002;11:310-319.
11. Chow KM, Wang AY, Hui AC, et al: Nonconvulsive status epilepticus in peritoneal dialysis patients. Am J Kidney Dis 2002;38:400-405.
12. Fountain NB: Status epilepticus: Risk factors and complications. Epilepsia 2000;41(Suppl 2):S23-S30.
13. Scholtes FB, Reiner WO, Meinardi H: Nonconvulsive status epilepticus: Causes, treatment and outcome in 65 patients. J Neurol Neurosurg Psychiatry 1996;61:93-95.
14. Shneker BF, Fountain NB: Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003;61: 1066-1073.
15. Murthy JM: Nonconvulsive status epilepticus: An underdiagnosed and potentially treatable condition. Neurol India 2003;51:453-454.
16. Kršek P, Mikullecká A, Druga R, et al: Long-term behavioral and morphological consequences of nonconvulsive status epilepticus in rats. Epilepsy Behav 2004;5:180-191.
17. Hirsch E, Genton P: Antiepileptic drug-induced pharmacodynamic aggravation of seizures. CNS Drugs 2003;17:1-8.
18. Genton P: When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80.
19. Lerman-Sagie T, Watemberg N, Kramer U, et al: Absence seizures aggravated by valproic acid. Epilepsia 2001;42:941-943.
20. Besag FMC, Wallace SJ, Dulac O, et al: Lamotrigine in the treatment of epilepsy in childhood. J Pediatr 1995;127:991-997.
21. Guerrini R, Dravet C, Genton P, et al: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-512.
22. Biraben A, Allain H, Scarabin JM, et al: Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.
23. Mewasingh LD, Sekhara T, Aeby A, et al: Oral ketamine in pediatric non-convulsive status epilepticus. Seizure 2003;12:483-489.
24. Gibbs JW, Zhang YF, Ahmed HS, Coulter DA: Anticonvulsant actions of lamotrigine on spontaneous thalamocortical rhythms. Epilepsia 2002;43:342-349.
25. Meeren H, van Luijtelaar G, Lopes da Silva F, Coenen A: Evolving concepts on the pathophysiology of absence seizures. Arch Neurol 2005;62:371-376.
26. Gross-Tsur V, Manor O, van der Meere J, et al: Epilepsy and attention deficit hyperactivity disorder. Is methylphenidate safe and effective? J Pediatr 1997;130:670-674.
27. Gucuyener K, Erdemoglu AK, Senol S, et al: Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003;18:109-112.